SKB Biopharmaceutical Gets China Marketing Nod for Nasopharyngeal Cancer

MT Newswires Live01-02

China's medical products administrator granted Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) marketing approval for a drug for recurrent or metastatic nasopharyngeal cancer, according to a Tuesday filing with the Hong Kong Exchange.

Tagitanlimab is indicated for patients whose treatments have failed following second-line chemotherapy, the filing said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment